Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease

Last updated: February 5, 2024
Sponsor: Concept Medical Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Claudication

Peripheral Vascular Disease

Peripheral Arterial Occlusive Disease

Treatment

MagicTouch PTA sirolimus drug coated balloon (DCB)

POBA standard balloon

Clinical Study ID

NCT04511234
FUTURE SFA
  • Ages > 21
  • All Genders

Study Summary

This study aims to conduct a randomized, double blind, randomised controlled multicentre trial of sirolimus drug coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial and popliteal arterial disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥ 21 years or minimum age
  2. Rutherford class 3 to 6 in the target limb Intraoperative Inclusion Criteria
  3. Single or sequential de novo or re-stenotic lesions (stenosis of > 50% or occlusions)from 2 to 20cm in the femoropopliteal arteries. Lesion is considered as one lesion ifthere is maximum of 30mm gap between lesions at discretion of investigator.Femoropopliteal arteries are superficial femoral artery, popliteal artery P1 and P2
  4. Inflow free from flow limiting lesions (<50% stenosis) confirmed by duplex orangiography. Subjects with flow limiting inflow lesions (>50% stenosis) can beincluded if lesion had been treated successfully (<30% residual stenosis) before orduring the index procedure.
  5. At least one non-occluded crural vessel (ie. without significant stenosis) withangiographically documented run off to the foot.

Exclusion

Exclusion Criteria:

  1. Comorbid conditions limiting life expectancy ≤ 1 year
  2. Subject is currently participating in another investigational drug or device studythat has not reached first primary endpoint yet
  3. Subject is pregnant or planning to become pregnant during the course of the study
  4. Heel gangrene
  5. Prior bypass surgery of target vessel
  6. Planned amputation of the target limb
  7. Previously implanted stent in the target lesion
  8. Vulnerable or protected adults
  9. Bleeding diathesis or another disorder such as gastrointestinal ulceration whichrestrict the use of clopidogrel or aspirin
  10. Known allergy to sirolimus Intraoperative Exclusion Criteria
  11. Failure to successfully cross the target lesion with a guide wire (successful crossingmeans tip of the guide wire distal to the target lesion in the absence of flowlimiting dissections or perforations)
  12. Failure to obtain <30% residual stenosis in a pre-existing lesion
  13. Highly calcific lesions
  14. Use of DCBs, drug eluting stent, specialty balloons or artherectomy devices during theindex procedure. (Non-compliant balloons are not considered specialty balloons)
  15. Lesions requiring retrograde access (SAFARI)

Study Design

Total Participants: 279
Treatment Group(s): 2
Primary Treatment: MagicTouch PTA sirolimus drug coated balloon (DCB)
Phase:
Study Start date:
September 08, 2020
Estimated Completion Date:
December 31, 2026

Study Description

The burden of limb loss as a result of peripheral arterial disease (PAD) is high and this problem is set to worsen globally. Treatment of PAD primarily involves revascularisation of the limb. Angioplasty as a first line strategy of revascularization over surgical procedures has been adopted by most vascular centers. Local drug delivery using drug coated balloons (DCB) during angioplasty for PAD can successfully deliver effective local tissue concentrations of anti-proliferative drugs to the lesions in the artery involved in the PAD. This offers the potential for sustained anti-restenotic efficacy.

Randomized trials have shown superiority of Paclitaxel DCBs over just plain-balloon angioplasty for treatment of PAD, and DCB is now considered the standard of care. However a recent meta-analyses which showed increased mortality at two years in patients treated with paclitaxel DCBs have called into question the safety of paclitaxel based DCBs.

Alternative drugs for DCBs are therefore urgently needed and sirolimus offers an attractive alternative. Compared to Paclitaxel, sirolimus is cytostatic in its mode of action with a high margin of safety. It has a high transfer rate to the vessel wall and has been shown to effectively inhibit neointimal hyperplasia in the porcine coronary model. In the coronary artery interventions, preliminary clinical studies using Sirolimus DCBs have also shown excellent procedural and 6 month patency.

Connect with a study center

  • Asan Medical Centre

    Seoul,
    Korea, Republic of

    Site Not Available

  • Khoo Teck Puat Hospital

    Singapore,
    Singapore

    Active - Recruiting

  • National University Hospital

    Singapore,
    Singapore

    Active - Recruiting

  • Ng Teng Fong General Hospital

    Singapore,
    Singapore

    Site Not Available

  • Sengkang General Hospital

    Singapore,
    Singapore

    Active - Recruiting

  • Singapore General Hospital

    Singapore,
    Singapore

    Active - Recruiting

  • Tan Tock Seng Hospital

    Singapore,
    Singapore

    Active - Recruiting

  • Far Eastern Memorial Hospital

    New Taipei City,
    Taiwan

    Site Not Available

  • Taipei Tzuchi Hospital

    New Taipei City,
    Taiwan

    Site Not Available

  • National Taiwan University Hospital

    Taipei City,
    Taiwan

    Site Not Available

  • Shin Kong Wu Ho-Su Memorial Hospital

    Taipei City,
    Taiwan

    Site Not Available

  • Taipei Mackay Memorial Hospital

    Taipei City,
    Taiwan

    Site Not Available

  • Linkou Chang Gung Memorial Hospital

    Taoyuan City,
    Taiwan

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.